◈ Nootpedia
Compact view
Research pass: medium Compound NOT-RELEVANT HIGH

Fluoxetine

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict NOT-RELEVANT HIGH

No clinical indication for Dylan. Longest half-life of SSRI class (less withdrawal but slower clearance) doesn't change the basic mismatch — emotional blunting + sexual dysfunction not justified absent diagnosis.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    NOT-RELEVANT
  • 30-50, executive maintenance
    NOT-RELEVANT

    unless clinical depression.

  • 50+, mild cognitive decline
    NOT-RELEVANT

    for cognition; caution re: drug interactions in polypharmacy elderly.

  • Anxiety-prone
    OPTIONAL-ADD

    if sertraline/escitalopram fail; activating profile may worsen acute anxiety.

  • High athletic load, tested status
    SKIP-FOR-NOW

    Same drive/libido concerns as class.

  • Sleep-disordered
    SKIP-FOR-NOW

    activating profile worsens insomnia in many.

  • Recovery-focused
    NOT-RELEVANT
  • Strength/anabolic-focused
    SKIP-PERMANENT
▸ Subjective experience (deep)

Activating profile vs sertraline (more daytime energy, sometimes anxiety/jitteriness early). Same emotional blunting and sexual dysfunction as class. Long half-life means missed doses are rarely felt; discontinuation is gentlest of SSRIs.

▸ Tolerance + cycling deep dive
  • Tolerance: Generally maintained; "poop-out" possible.
  • Not cycled; chronic use.
▸ Stacking deep dive

Avoid stacking with

  • MAOIs: 5-week washout required (vs 14 days for other SSRIs) due to long half-life.
  • Tramadol, MDMA, 5-HTP, St John's wort: serotonin syndrome.
  • Tamoxifen: fluoxetine inhibits CYP2D6 → reduces tamoxifen activation → reduced anti-cancer efficacy.
▸ Drug interactions deep dive

Strong CYP2D6 + moderate CYP2C19 inhibitor. Many interactions (TCAs, antipsychotics, beta-blockers, codeine/tramadol). Worst interaction profile of SSRI class along with paroxetine.

▸ Pharmacogenomics

CYP2D6 PM/UM affects metabolism modestly. Self-inhibits CYP2D6 at clinical doses, reducing the impact of phenotype.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Rx Pharmacy $4-15/mo generic high Cheapest SSRI; widely available.
▸ Biomarkers to track (deep)
  • Baseline: PHQ-9, GAD-7, sodium, LFTs.
  • During use: PHQ-9 q4-6 weeks; sodium at 2 + 8 weeks; sexual function check.
  • Post-discontinuation: Recognize 4-6 week pharmacological tail when starting new agents.
▸ Controversies / open debates Live debate
  • Pediatric use: Only SSRI with FDA approval for adolescent MDD; controversy over benefit:risk in this group continues.
  • Tamoxifen interaction: Real impact on breast cancer outcomes via CYP2D6 inhibition; switch to citalopram/escitalopram for breast cancer survivors.
  • Bulimia mechanism: Unique 5-HT2C effect proposed; clinical efficacy at 60mg.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: NOT-RELEVANT.
▸ Open questions / gaps Open

Whether long half-life provides meaningful clinical advantage (compliance, withdrawal) over shorter SSRIs. Real-world tamoxifen interaction magnitude.

▸ Sources (full, with our context)
Back to compact view